Test Price
2,800 AED✅ Home Collection Available
PRKCG Gene Spinocerebellar Ataxia Type 14 (Autosomal Dominant) – Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO 15189-accredited NGS workflow with Sanger confirmation.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection (daily 8 AM – 11 PM).
- Post-Test Guidance: Complimentary telephonic clinical interpretation with a DHA-licensed genetic counsellor.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test analyses the entire coding sequence of the PRKCG gene to identify pathogenic variants associated with Spinocerebellar Ataxia Type 14 (SCA14), an autosomal dominant neurodegenerative disorder. It is the definitive molecular diagnostic tool for patients with progressive ataxia and a family history suggestive of SCA14, enabling accurate prognosis, family risk assessment, and personalized management.
| Feature | Our Test (PRKCG NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Technology | Targeted NGS with full exon coverage & Sanger validation | Whole Exome Sequencing (WES) |
| Diagnostic Precision | 99.9% sensitivity for PRKCG variants | May incidentally detect SCA14 but lower depth of coverage |
| Turnaround Time | 3–4 weeks | 8–12 weeks typical |
| Cost-Effectiveness | 2800 AED – focused, no incidental findings | Often >5000 AED, with complex interpretation |
| Clinical Actionability | Direct diagnosis & family counselling | Requires secondary confirmation & additional tests |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasise that a positive PRKCG variant provides a definitive molecular diagnosis of SCA14, enabling accurate recurrence risk counselling for families. However, clinical correlation with neurological presentation and imaging is essential. I strongly advocate for pre- and post-test genetic counselling to guide patients through the implications of hereditary ataxia testing.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
⚠️ Medication Warning
Do not discontinue or adjust any prescribed medication without consulting your treating physician. Genetic test results are not a substitute for ongoing neurological care.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent; severe cognitive or psychiatric impairment that limits understanding of genetic implications; minors must have legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: Rapid progression of ataxia with loss of independent ambulation within weeks, acute vision loss, severe dysphagia, or respiratory distress — seek immediate emergency medical attention.
Patient FAQ & Clinical Guidance
1. How does this PRKCG genetic test confirm spinocerebellar ataxia type 14?
This test sequences the entire coding region of the PRKCG gene to detect pathogenic variants causing autosomal dominant SCA14, delivering a definitive molecular diagnosis that clarifies prognosis and family risk.
2. What is the turnaround time for results and how are they delivered?
Results are typically available within 3 to 4 weeks from sample receipt, and are delivered through a secure online portal with a comprehensive clinical report, followed by an optional telephonic consultation with a genetic counsellor.
3. Is home sample collection available for this test in the UAE?
Yes, our DHA-licensed mobile phlebotomy team provides hospital-grade home blood collection across all emirates, using ISO-certified cold-chain transport, available daily from 8 AM to 11 PM.
UAE Regulatory & Data Privacy Adherence
Data Privacy and Security: This test service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, stored securely, and accessed only by authorised personnel.
Clinical Safety and Consent: The collection and handling of genetic material follows the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent, patient autonomy, and safe clinical practices.
Laboratory Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | DHA Facility License No. 1143
Clinical & Logistical Metadata
| Test Name | PRKCG Gene Sequencing (SCA14) – Next-Generation Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card (One Drop Blood) |
| Methodology Used | Targeted NGS with Sanger confirmation (ISO 15189 accredited) |
| ICD-10-CM Code | G11.8 (Other hereditary ataxias), Z14.8, R27.0 |
| LOINC Code | 81247-7 – PRKCG gene targeted mutation analysis |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians